(S)-2-(chroman-4-ylamino)-1-(7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl)-ethanone trifluoroacetate | 928314-69-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (S)-2-(chroman-4-ylamino)-1-(7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl)-ethanone trifluoroacetate
• 英文别名: 2-[[(4S)-3,4-dihydro-2H-chromen-4-yl]amino]-1-[7-(trifluoromethyl)-3,4-dihydro-2H-quinolin-1-yl]ethanone;2,2,2-trifluoroacetic acid
• CAS: 928314-69-6
• 化学式: C₂HF₃O₂*C₂₁H₂₁F₃N₂O₂
• 分子量: 504.429
• InChiKey: YBRXMQHHTRIQAA-LMOVPXPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.73
• 重原子数：
  35
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  11

文献信息

• Organic Compounds
  申请人：Flor Peter Josef

  公开号：US20080242698A1

  公开（公告）日：2008-10-02

  The invention relates to novel diamines of the formula in which all variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

  本发明涉及一种新型二胺化合物，其化学式为，在该式中所有变量均如规范中定义，其为自由碱基形式或酸加成盐形式，涉及其制备方法，以及作为药物的用途和包含它们的药物。
• Organic diamines as mGluR7 modulators
  申请人：NOVARTIS AG

  公开号：EP2096104A1

  公开（公告）日：2009-09-02

  The invention relates to novel diamines of the formula in which all variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

  本发明涉及式如下的新型二胺 其中所有变量均如说明书中所定义，以游离碱形式或酸加成盐形式存在，涉及它们的制备、作为药物的用途以及包含它们的药物。
• ORGANIC COMPOUNDS
  申请人：Novartis Pharma AG

  公开号：EP1924551A2

  公开（公告）日：2008-05-28
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSES ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2007025709A2

  公开（公告）日：2007-03-08

  [EN] The invention relates to novel diamines of the formula (I) in which all variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
  [FR] Diamines de formule (I), les variables de cette formule étant telles que définies dans la description, sous forme de base libre ou de sel d'addition d'acide, ainsi que leur élaboration, leur utilisation comme médicaments, et enfin médicaments les renfermant.